This article is more than 5 years old. Information may no longer be current.

New drug could help prevent onset of obesity-related type 2 diabetes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Results from preclinical studies showed a novel therapy increased insulin sensitivity among treatment groups on a high-fat diet, stopped fat mass increase and prevented type 2 diabetes, according to a press release from the institution.

The new drug, developed by scientists at Ohio University Heritage College of Osteopathic Medicine in Athens, Ohio, may hold potential for halting the onset of obesity-related type 2 diabetes, according to researchers.

“The implications are enormous,” Kelly McCall, PhD, associate professor of endocrinology at the institution, said in a press release. “This drug could significantly change the treatment protocol for type 2 diabetes.”

McCall and colleagues are investigating the effects of the drug, C-10, on various autoimmune-inflammatory diseases. Early findings showing C-10 successfully blocks a key pathway involved in the diseases suggests the therapy could potentially slow or stop type 2 diabetes, according to the release.

The therapy is currently awaiting clinical trials.